Loss-of-function mutations of STXBP1 in patients with epileptic encephalopathy

Toshiyuki Yamamoto1, Keiko Shimojima1, Tamami Yano2

  • 1Tokyo Women's Medical University Institute for Integrated Medical Sciences, Tokyo, Japan.

Brain & Development
|September 20, 2015
PubMed

Insights

Syntaxin-binding protein 1 gene (STXBP1) mutations cause early infantile epileptic encephalopathy. This study found four novel STXBP1 mutations, all leading to loss-of-function, suggesting it

Area of Science:

  • Genetics and Neurology
  • Neurodevelopmental Disorders

Background:

  • Epileptic encephalopathy is a severe infantile-onset epilepsy characterized by age-dependent seizures and profound developmental delay.
  • Mutations in the syntaxin-binding protein 1 gene (STXBP1) are a known cause of epileptic encephalopathy.

Purpose of the Study:

  • To investigate the role of STXBP1 mutations in a cohort of patients with early infantile epileptic encephalopathy.
  • To identify novel mutations in STXBP1 and elucidate their functional consequences.

Main Methods:

  • A cohort study was conducted involving 42 patients diagnosed with epileptic encephalopathy.
  • Genetic analysis was performed to identify mutations in the STXBP1 gene.
  • In silico prediction tools were used to assess the functional impact of identified mutations.

Main Results:

  • Four novel STXBP1 mutations were identified: two splicing mutations, one frameshift mutation, and one nonsense mutation.
  • All identified mutations were predicted to result in a loss-of-function of the STXBP1 protein.
  • Patients with STXBP1 mutations exhibited typical epileptic features but showed variable radiological findings, including reduced brain volume and delayed myelination.

Conclusions:

  • Loss-of-function is a prevalent mechanism underlying STXBP1-related epileptic encephalopathy.
  • STXBP1 mutations are a significant genetic cause of early infantile epileptic encephalopathy.
  • While epileptic features are consistent, radiological manifestations in STXBP1-related disorders can be diverse.

Related Concept Videos

Pleiotropy01:33

Pleiotropy

Pleiotropy is the phenomenon in which a single gene impacts multiple, seemingly unrelated phenotypic traits. For example, defects in the SOX10 gene cause Waardenburg Syndrome Type 4, or WS4, which can cause defects in pigmentation, hearing impairments, and an absence of intestinal contractions necessary for elimination. This diversity of phenotypes results from the expression pattern of SOX10 in early embryonic and fetal development. SOX10 is found in neural crest cells that form melanocytes,...
44.1K
Alternative RNA Splicing02:18

Alternative RNA Splicing

Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
26.8K
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.7K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.1K
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.7K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
966